NCT03976362 2026-02-25
KEYLYNK-008
Merck Sharp & Dohme LLC
Phase 3 Completed
Clinical Trials
7 trialsNCT03498521 2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2 Completed
NCT04197713 2025-10-20
Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT03842228 2025-10-14
COD
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02576444 2022-12-28
OLAPCO
Yale University
Phase 2 Terminated
NCT02093351 2019-10-02
To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer
AstraZeneca
Phase 1 Completed
NCT01813474 2018-01-16
Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies
AstraZeneca
Phase 1 Completed